این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Blood and Cancer، جلد ۸، شماره ۱، صفحات ۹-۱۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
چکیده انگلیسی مقاله Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new cases with Philadelphia chromosome-positive CML without any underlying thyroid disorder or drug history interfering with Imatinib mesylate were enrolled. Thyroid function tests including serum Thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), anti-thyroid peroxidase (Anti-TPO) and anti-thyroglobulin (Anti-Tg) were assessed at baseline and during follow-up. Results: Mean age at diagnosis was 60.4 years. 14 (70%) patients were male. Mean value for TSH, FT4, FT3, Anti-TPO, and Anti-Tg before treatment were 2.82 mIU/L, 1.39 ng/dl, 325.50 ng/dl, 30.35 IU/ml and 39.40 IU/ml, respectively. The mean value for TSH, FT4, FT3 and Anti-TPO 1, 3, 6, and 12 months after initiation of Imatinib mesylate were not statistically significant. Conclusion: Based on the results of the study, there was no significant change in thyroid function tests during treatment with Imatinib mesylate and all laboratory variables were in normal ranges. 
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله ابوالقاسم الهیاری | abolghasem allahyari
department of hematology-oncology, emam reza hospital, school of medicine, mashhad university of medical sciences, mashhad, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)

فروغ صالحی | foroogh salehi
department of endocrinology, vali asr hospital, school of medicine, birjand university of medical sciences, birjand, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی بیرجند (Birjand university of medical sciences)

مصطفی کابلی | mostafa kaboli
department of internal medicine, school of medicine, birjand university of medical sciences, birjand, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی بیرجند (Birjand university of medical sciences)

مسعود صادقی | masoud sadeghi
cancer research center, kermanshah university of medical sciences, kermanshah, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی کرمانشاه (Kermanshah university of medical sciences)

نشانی اینترنتی http://www.ijbc.ir/browse.php?a_code=A-10-218-8&slc_lang=en&sid=en
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده 0|
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات